Motixafortide

FDA-approved context Healing & Recovery 2 sources

Motixafortide is a potent, long-acting CXCR4 antagonist that stimulates the release of hematopoietic stem cells from the bone marrow into the peripheral blood. It is FDA-approved for use in combination with filgrastim to mobilize stem cells for collection and autologous transplantation in patients with multiple myeloma.

01Dosing reference

Amount

1.25 mg/kg

Frequency

Single dose

Cycle

Administered 10 to 14 hours prior to the initiation of apheresis

Reference figures, not a recommendationThese values reflect amounts described in the literature and vendor documentation this database indexes. Use the reconstitution calculator to convert them into syringe units.

02Mechanism of action

CXCR4 Antagonism

Motixafortide binds to the CXCR4 receptor on hematopoietic stem cells, blocking its interaction with the SDF-1 (CXCL12) ligand.

Stem Cell Mobilization

Blocking this interaction disrupts the retention of stem cells in the bone marrow, causing them to migrate into the peripheral blood.

Enhanced Collection

This allows for a higher yield of stem cells during apheresis, improving the success of autologous stem cell transplants.

03Human evidence

Significantly improved stem cell mobilization in multiple myeloma patients.

The Phase 3 GENESIS trial showed that motixafortide plus filgrastim enabled 92.5% of patients to collect the target number of stem cells in up to two apheresis sessions, compared to 26.2% with filgrastim alone.

Rapid mobilization allowing single-session collection.

The majority of patients in the GENESIS trial achieved the target stem cell yield in just one apheresis session, reducing the burden on patients and healthcare systems.

04Preclinical evidence

Prolonged receptor occupancy.

Animal models demonstrated that motixafortide has a much longer half-life and receptor occupancy compared to earlier CXCR4 antagonists like plerixafor.

Potential in solid tumors.

Preclinical studies in pancreatic cancer models suggest that blocking CXCR4 with motixafortide can alter the tumor microenvironment and enhance the efficacy of immunotherapies.

05What is known vs. unknown

Reasonably established

FDA-approved for stem cell mobilization in multiple myeloma patients.
Acts as a highly potent and long-acting CXCR4 antagonist.
Administered via subcutaneous injection prior to apheresis.
Significantly reduces the number of apheresis sessions needed to collect sufficient stem cells.

Unknowns & limits

Its efficacy and safety in mobilizing stem cells for other types of cancers or healthy donors are still under investigation.
The long-term effects of prolonged CXCR4 blockade in combination therapies for solid tumors remain to be fully established.

06Safety & regulatory context

Regulatory statusMotixafortide (brand name Aphexda) is FDA-approved for stem cell mobilization in multiple myeloma. Common side effects include injection site reactions (pain, erythema, pruritus), flushing, and back pain. Severe hypersensitivity reactions, including anaphylaxis, have been reported, necessitating premedication and monitoring. It is contraindicated in patients with a history of severe hypersensitivity to the drug.

07Compared with Plerixafor

Motixafortide vs. Plerixafor

Key difference

Motixafortide has a significantly longer receptor occupancy and half-life, leading to more sustained stem cell mobilization.

When researchers discuss each

Plerixafor is discussed as the first-generation CXCR4 antagonist for stem cell mobilization, while motixafortide is highlighted as a next-generation, longer-acting alternative that often requires fewer apheresis sessions.

08Glossary

CXCR4

A chemokine receptor on cells that, when bound to its ligand CXCL12, helps keep stem cells anchored in the bone marrow.

Apheresis

A medical procedure where blood is drawn, a specific component (like stem cells) is separated and collected, and the rest of the blood is returned to the body.

Autologous stem cell transplant

A procedure where a patient's own stem cells are collected and later reinfused to help the bone marrow recover after high-dose chemotherapy.

09Knowledge check

Q1What is the primary mechanism of action of motixafortide?

Q2What is the main clinical purpose of motixafortide in multiple myeloma patients?

Q3Which documented limitation about motixafortide is stated in the dossier?

Q4According to the dossier, how does motixafortide compare with the first-generation CXCR4 antagonist plerixafor?

Q5Which statement about motixafortide's regulatory status and safety precautions is supported by the dossier?

10Sources

More in Healing & Recovery

See all

BPC-157

Healing & Recovery

Early human

BPC-157 is a synthetic peptide sequence based on a protective compound naturally found in human gastric juice. Research suggests it has significant regenerative properties, promoting the healing of tendons, ligaments, muscles, and the gastrointestinal tract by accelerating angiogenesis and modulating growth factors.

250-500 mcg

TB-500 (Thymosin Beta-4)

Healing & Recovery

Early human

TB-500 is a synthetic version of the naturally occurring peptide Thymosin Beta-4. Research indicates it plays a crucial role in tissue repair, wound healing, and reducing inflammation by upregulating actin, a vital protein for cell structure and movement.

2.0 - 2.5 mg per injection

KPV

Healing & Recovery

Early human

KPV (Lys-Pro-Val) is a naturally occurring tripeptide derived from alpha-melanocyte-stimulating hormone (alpha-MSH). Research highlights its potent anti-inflammatory and antimicrobial properties, making it a promising candidate for conditions like inflammatory bowel disease, skin disorders, and wound healing.

200-500 mcg/day

Research and educational use onlyNothing on this site is medical advice, a prescription, or a recommendation for human use. Compounds documented here are research chemicals. Consult a qualified clinician before making any health decision.